112 related articles for article (PubMed ID: 25065175)
1. [Diabetes mellitus type 2 the status of future therapy with GPR40 agonists].
Verspohl EJ
Med Monatsschr Pharm; 2014 Jul; 37(7):275. PubMed ID: 25065175
[No Abstract] [Full Text] [Related]
2. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
3. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
4. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
Choi YJ; Shin D; Lee JY
Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
[TBL] [Abstract][Full Text] [Related]
5. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
6. Predicting GPR40 Agonists with A Deep Learning-Based Ensemble Model.
Yang J; Jiang C; Chen J; Qin LP; Cheng G
ChemistryOpen; 2023 Nov; 12(11):e202300051. PubMed ID: 37404062
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
9. Molecule of the Month. TAK-875.
Drug News Perspect; 2010 Dec; 23(10):667. PubMed ID: 21180652
[No Abstract] [Full Text] [Related]
10. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
[TBL] [Abstract][Full Text] [Related]
11. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Henke BR
J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
[No Abstract] [Full Text] [Related]
13. Management of type 2 diabetes mellitus with oral antihyperglycaemic therapy.
Desai A; Tandon N
Natl Med J India; 2007; 20(4):192-8. PubMed ID: 18085125
[No Abstract] [Full Text] [Related]
14. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.
Phillippe HM; Wargo KA
Ann Pharmacother; 2010 Oct; 44(10):1615-23. PubMed ID: 20841518
[TBL] [Abstract][Full Text] [Related]
15. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
16. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
17. A promising horizon. New treatment choices for diabetes.
Leccese C
Adv Nurse Pract; 1997 Oct; 5(10):60-2. PubMed ID: 9459988
[No Abstract] [Full Text] [Related]
18. [Thiazolidenediones, diabetes and adipogenesis].
Moreno L; Barettino D
Med Clin (Barc); 1999 Apr; 112(12):457-8. PubMed ID: 10320960
[No Abstract] [Full Text] [Related]
19. [New hypoglycemic drugs in treatment of diabetes type 2].
Sokup A; Swiatkowski M
Przegl Lek; 2000; 57(6):349-52. PubMed ID: 11107871
[TBL] [Abstract][Full Text] [Related]
20. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
